Lipid peroxidation

Study Illustrates Zeropollution's Enhancing Skin's Resilience to Environmental Damage

Retrieved on: 
Tuesday, March 5, 2024

MADRID, March 5, 2024 /PRNewswire/ -- A new, preclinical study highlights the abilities of a beauty-from-within botanical-blend Zeropollution® to shield skin from the adverse effects of city pollution, especially from free radical damage on a cellular level.

Key Points: 
  • This patented multi-herbal cosmeceutical has been crafted to synergistically strengthen the skin's protective barrier against environmental insults through an "inside out" approach.
  • The study led by Laurent Peno-Mazzarino was published in the Journal of Current Issues in Molecular Biology in January 2024.
  • This encompasses reactive molecules generated by factors such as UV radiation, pollution, and other environmental stressors that can damage cells and tissues.
  • In this study, Zeropollution successfully counteracted the adverse effects of urban dust on the heart rate of zebra fish embryos.

Solésence Beauty Science is Named Winner of the 22nd Annual Chicago Innovation Awards

Retrieved on: 
Wednesday, November 29, 2023

ROMEOVILLE, Ill., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Solésence Beauty Science, a leader in inclusive, mineral-based beauty products for skincare and makeup brands and a wholly owned subsidiary of Nanophase Technologies Corporation, today announced that it has been named one of the winners of the 22nd annual Chicago Innovation Awards.

Key Points: 
  • ROMEOVILLE, Ill., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Solésence Beauty Science, a leader in inclusive, mineral-based beauty products for skincare and makeup brands and a wholly owned subsidiary of Nanophase Technologies Corporation, today announced that it has been named one of the winners of the 22nd annual Chicago Innovation Awards.
  • The annual Chicago Innovation Awards is the Chicago region’s foremost recognition of the most innovative new products or services brought to market each year.
  • The Company was named for the Solésence Kleair™ technology, which is available exclusively through Solésence finished goods.
  • “The Chicago region continues to be a global leader in innovation,” said Tom Kuczmarski, co-founder with Chicago journalist Dan Miller of the awards.

Sonata Therapeutics Presents Data Supporting its Network Medicines™ Approach at SITC 2023

Retrieved on: 
Friday, November 3, 2023

Sonata Therapeutics, Inc., a biotechnology company developing a new class of therapeutics called Network Medicines™, will present three posters at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.

Key Points: 
  • Sonata Therapeutics, Inc., a biotechnology company developing a new class of therapeutics called Network Medicines™, will present three posters at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.
  • In contrast, Sonata’s Network Medicines target pathways that change the complete dynamics of multifactorial diseases, resulting in more durable therapeutics and potentially better outcomes for patients.
  • Data demonstrate that ferroptosis induction is a promising strategy for the treatment of sarcomas, supporting Sonata’s continued investigation in syngeneic mouse models.
  • “Through our proprietary platform, Sonata is generating Network Medicines that move beyond the current immunotherapeutic paradigm.

Solésence Beauty Science Named One of the Top 100 Finalists for the 22nd Annual Chicago Innovation Awards

Retrieved on: 
Tuesday, October 3, 2023

ROMEOVILLE, Ill., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Solésence Beauty Science, a wholly owned subsidiary of Nanophase Technologies Corporation, today announced that it has been selected as one of the Top 100 Finalists still in the running for the 22nd annual Chicago Innovation Awards .

Key Points: 
  • ROMEOVILLE, Ill., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Solésence Beauty Science, a wholly owned subsidiary of Nanophase Technologies Corporation, today announced that it has been selected as one of the Top 100 Finalists still in the running for the 22nd annual Chicago Innovation Awards .
  • The Company was named for the Solésence Kleair™ technology, which is available exclusively through Solésence finished goods.
  • “We are honored to see Solésence Kleair™ among an impressive group of nominees for the 22nd annual Chicago Innovation Awards.
  • Out of the Top 100 Finalists, the judges will select 20 winners of the Chicago Innovation Awards.

Keto diet may slow cancer tumour growth in mice – but not without potentially deadly consequences

Retrieved on: 
Saturday, June 17, 2023

A recently published study in mice has now shown that the keto diet may also have use in treating tumours.

Key Points: 
  • A recently published study in mice has now shown that the keto diet may also have use in treating tumours.
  • The mice were then allocated into two groups: one group was fed a standard diet while the other group was fed a high-fat, low carb keto diet.
  • Over the course of the next month, the investigators found that mice on the keto diet showed slower tumour growth than the mice fed a standard diet.

Keto and cancer

    • Since cancer cells grow quickly, they have much higher energy needs – so they rely solely on glucose for energy.
    • But since the keto diet has a very low carbohydrate intake, it’s thought that this “starves” the cancer cells of the energy they need to grow.
    • Keto also kick-starts a process called lipid peroxidation, which causes the body to use fats for the energy it needs instead.

Cancer treatment

    • At the moment, there are a number of ongoing trials and some emerging evidence suggesting the keto diet has beneficial effects on many types of cancer.
    • Second, patients who follow a keto diet will experience different benefits depending on the stage of their cancer.
    • Chemotherapy targets rapidly growing cells – and so in a fasted state, it will target the cancer cells instead, leaving healthy cells safe.
    • Given there’s still so much we don’t know, it’s advised that patients undergoing cancer treatment speak with their medical practitioner about any diet changes they may be planning to make.

Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye Disease

Retrieved on: 
Tuesday, November 29, 2022

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for topical ocular reproxalap, an investigational new drug candidate, for the treatment of signs and symptoms of dry eye disease.

Key Points: 
  • Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for topical ocular reproxalap, an investigational new drug candidate, for the treatment of signs and symptoms of dry eye disease.
  • With data suggesting activity within minutes of administration, reproxalap could provide an important treatment option for the millions of dry eye patients who generally regard currently available therapies as inadequate.
  • Reproxalap is the lead product candidate in Aldeyras RASP modulator platform, which includes systemic disease pipeline candidates ADX-629 and related analogs.
  • In addition to dry eye disease, reproxalap is in late-stage development for allergic conjunctivitis, a condition that is commonly associated with dry eye disease.

Insights on the Feed Antioxidants Global Market to 2027 - Asia-pacific Dominates the Global Market - ResearchAndMarkets.com

Retrieved on: 
Monday, October 10, 2022

Increased global poultry meat consumption and the rising health concerns in livestock led to higher consumption of antioxidants.

Key Points: 
  • Increased global poultry meat consumption and the rising health concerns in livestock led to higher consumption of antioxidants.
  • According to the Food and Agriculture Organization, the consumption of poultry meat showed a consistent growth from 2017 to 2020.
  • Poultry feed takes up a significant share of antioxidants, followed by dairy and beef feed antioxidants.
  • The rising cost of feed worldwide is the key factor driving up demand for feed antioxidants to prevent spoiling and extend the shelf life.

Aldeyra Therapeutics Announces Positive Dry Eye Disease Pre-NDA Meeting with the FDA and Highlights Upcoming Corporate Milestones

Retrieved on: 
Wednesday, September 14, 2022

In addition to the planned NDA submission for reproxalap in dry eye disease, Aldeyra highlighted the following expected upcoming corporate milestones:

Key Points: 
  • In addition to the planned NDA submission for reproxalap in dry eye disease, Aldeyra highlighted the following expected upcoming corporate milestones:
    The pre-NDA meeting for ADX-2191 for the treatment of primary vitreoretinal lymphoma has been scheduled for the fourth quarter of 2022.
  • Results from the Phase 2 clinical trial of ADX-2191 in retinitis pigmentosa are expected in the first half of 2023.
  • Among many physicians and patients, existing therapy for dry eye disease is generally regarded as inadequate and often requires weeks or months to demonstrate activity.
  • Expression of Lipid Peroxidation Markers in the Tear Film and Ocular Surface of Patients with Non-Sjogren Syndrome: Potential Biomarkers for Dry Eye Disease.

Hillstream BioPharma Announces Collaboration with Sapien Biosciences in Cancer Treatments

Retrieved on: 
Monday, June 27, 2022

The study concluded that inducing the Ferroptotic pathway in combination with checkpoint blockade is a potential synergistic therapeutic approach.

Key Points: 
  • The study concluded that inducing the Ferroptotic pathway in combination with checkpoint blockade is a potential synergistic therapeutic approach.
  • We are initiating studies, in collaboration with Sapien Biosciences, to determine the synergy between HSB-1216, our ferroptosis inducer and nivolumab, an anti-PD1 antibody, said Randy Milby, Hillstreams Chief Executive Officer.
  • We are excited to extend our collaboration with Hillstream Biopharma to evaluate potential synergy between their HSB-1216 molecule and ICIs using our expertise in establishing patient tissue-derived cell models in oncology, immunology and Immune-oncology,said Dr. Jugnu Jain, CEO, Sapien Biosciences.
  • Previously, Sapien demonstrated potent anti-cancer activity of HSB-1216 in primary triple negative breast cancer cells which were presented at AACR 2020.

Aldeyra Therapeutics Announces Positive Top-Line Data from Phase 2 Dry Eye Chamber Clinical Trial of Reproxalap, an Investigational New Drug, Compared to Xiidra®

Retrieved on: 
Tuesday, January 11, 2022

The double-masked, crossover, single-center, Phase 2 clinical trial in 56 dry eye disease patients evaluated the activity of reproxalap compared to Xiidra for two endpoints: ocular discomfort symptom score and ocular itching symptom score.

Key Points: 
  • The double-masked, crossover, single-center, Phase 2 clinical trial in 56 dry eye disease patients evaluated the activity of reproxalap compared to Xiidra for two endpoints: ocular discomfort symptom score and ocular itching symptom score.
  • Symptoms were assessed approximately 15 minutes prior to chamber entry, and every 5 minutes beginning 5 minutes after chamber entry.
  • Reproxalap is in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis.
  • Expression of Lipid Peroxidation Markers in the Tear Film and Ocular Surface of Patients with Non-Sjogren Syndrome: Potential Biomarkers for Dry Eye Disease.